- Trials with a EudraCT protocol (72)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
72 result(s) found for: Orphan Drug.
Displaying page 1 of 4.
EudraCT Number: 2021-004002-21 | Sponsor Protocol Number: Bio-Eq-20 | Start Date*: 2021-11-26 | |||||||||||
Sponsor Name:AOP Orphan Pharmaceuticals GmbH | |||||||||||||
Full Title: A single center, open-label, two-period, non-randomized, paired-design study to compare steady-state plasma levels following switch from a 10 mg/ml treprostinil formulation to a 20 mg/ml treprostin... | |||||||||||||
Medical condition: pulmonary arterial hypertension | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-002806-10 | Sponsor Protocol Number: SOBI003-001 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Swedish Orphan Biovitrum AB (publ) | |||||||||||||
Full Title: An open, non-controlled, parallel, ascending multiple-dose, multicenter study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of SOBI003 in pediatric MPS IIIA patients | |||||||||||||
Medical condition: Mucopolysaccharidosis Type IIIA or Sanfilippo Syndrome | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) NL (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-002502-31 | Sponsor Protocol Number: RP-L102-0118 | Start Date*: 2018-10-31 | |||||||||||
Sponsor Name:Rocket Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Phase II Clinical Trial to Evaluate the Efficacy of the Infusion of Autologous CD34+ Cells Transduced with a Lentiviral Vector Carrying the FANCA Gene (Orphan Drug) in Patients with Fanconi Anemi... | |||||||||||||
Medical condition: Fanconi anemia (subtype A) | |||||||||||||
|
|||||||||||||
Population Age: Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-001577-24 | Sponsor Protocol Number: NI-0501-14 | Start Date*: 2021-12-15 | |||||||||||
Sponsor Name:Swedish Orphan Biovitrum AG (Sobi AG) | |||||||||||||
Full Title: A two-cohort, open-label, single arm, multicenter study to evaluate efficacy, safety and tolerability, pharmacokinetics and pharmacodynamics, of emapalumab in children and adults with macrophage ac... | |||||||||||||
Medical condition: Macrophage activation syndrome (MAS) in the context of Systemic juvenile inflammatory arthritis (sJIA) and Adult onset Still’s disease (AOSD). MAS in the context of pediatric and adult Systemic lup... | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) FR (Ongoing) IT (Ongoing) PL (Ongoing) DE (Ongoing) CZ (Ongoing) BE (Ongoing) SE (Ongoing) NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-003725-42 | Sponsor Protocol Number: R121178 | Start Date*: 2018-03-23 | |||||||||||
Sponsor Name:University of Manchester | |||||||||||||
Full Title: Does Interleukin-1 Receptor Antagonist Improve Outcome following aneurysmal Subarachnoid Haemorrhage (aSAH)? A Phase III trial | |||||||||||||
Medical condition: subarachnoid haemorrhage | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-003160-27 | Sponsor Protocol Number: Sobi.PEGCET-101 | Start Date*: 2022-05-31 |
Sponsor Name:Swedish Orphan Biovitrum AB | ||
Full Title: A Phase 3, Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Patients with Cold Agglutinin Disease (CAD) | ||
Medical condition: Patients with Cold Agglutinin Disease (CAD) | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: DE (Prematurely Ended) NO (Prematurely Ended) HU (Prematurely Ended) AT (Prematurely Ended) IT (Prematurely Ended) BG (Prematurely Ended) ES (Prematurely Ended) FI (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2012-005259-18 | Sponsor Protocol Number: PROUD-PV | Start Date*: 2013-08-15 | |||||||||||
Sponsor Name:AOP Orphan Pharmaceuticals AG | |||||||||||||
Full Title: A randomized, open-label, multicenter, controlled, parallel arm, phase III study assessing the efficacy and safety of AOP2014 vs. Hydroxyurea in patients with Polycythemia Vera | |||||||||||||
Medical condition: Polycythemia Vera | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) CZ (Completed) IT (Completed) SK (Completed) AT (Completed) BG (Completed) DE (Completed) PL (Completed) ES (Completed) BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-003825-81 | Sponsor Protocol Number: HGT-FIR-086 | Start Date*: 2012-02-28 | |||||||||||
Sponsor Name:Shire Orphan Therapies, Inc | |||||||||||||
Full Title: A Multicenter, Open-Label, Non-Randomized Study to Assess the Pharmacokinetics, Tolerability, and Safety of a Single Subcutaneous Administration of Icatibant in Children and Adolescents with Heredi... | |||||||||||||
Medical condition: Hereditary Angioedema | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) HU (Prematurely Ended) ES (Prematurely Ended) IT (Completed) AT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-000075-27 | Sponsor Protocol Number: HPN-100-021 | Start Date*: 2017-05-04 | |||||||||||
Sponsor Name:Horizon Therapeutics, LLC | |||||||||||||
Full Title: A Randomised, Controlled, Open-Label Parallel Arm Study of the Safety, Pharmacokinetics and Ammonia Control of RAVICTI® (Glycerol Phenylbutyrate [GPB]) Oral Liquid and Sodium Phenylbutyrate (NaPBA)... | |||||||||||||
Medical condition: Urea Cycle Disorders (UCDs) | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Ongoing) GB (Completed) AT (Completed) IT (Completed) ES (Ongoing) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-002773-64 | Sponsor Protocol Number: RP103-07 | Start Date*: 2014-01-22 | |||||||||||
Sponsor Name:Horizon Pharma USA, Inc. | |||||||||||||
Full Title: A Long-Term Open-Label, Safety and Superior Effectiveness Study of Cysteamine Bitartrate Delayed-release Capsules (RP103) in Patients with Cystinosis | |||||||||||||
Medical condition: Cystinosis | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) BE (Completed) NL (Completed) IT (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-004974-16 | Sponsor Protocol Number: IL1ra03 | Start Date*: 2018-11-08 | ||||||||||||||||
Sponsor Name:Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge | ||||||||||||||||||
Full Title: DOUBLE-BLIND PLACEBO-CONTROLLED RANDOMISED CLINICAL DOSE-RANGING STUDY TREATING MODERATE-SEVERE TRAUMATIC BRAIN INJURY PATIENTS WITH RECOMBINANT HUMAN INTERLEUKIN 1 RECEPTOR ANTAGONIST. | ||||||||||||||||||
Medical condition: We wish to study the drug Kineret in patients suffering from moderate-to-severe traumatic brain injury | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2010-021384-33 | Sponsor Protocol Number: NTXMR1 | Start Date*: 2010-08-20 |
Sponsor Name:Beroendecentrum Stockholm | ||
Full Title: The Effect of Naltrexone on Amphetamine Cue Reactivity: An fMRI Study | ||
Medical condition: Amphetamine dependence | ||
Disease: | ||
Population Age: Adults | Gender: Male | |
Trial protocol: SE (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2008-007104-28 | Sponsor Protocol Number: IFN-Multiferon08 | Start Date*: 2009-04-01 |
Sponsor Name:Karolinska Universitetssjukhuset | ||
Full Title: Multiferon treatment of non-responders to peg-IFN alfa plus ribavirin standard of care treatment - a study of the early viral kinetics during the initial 12 weeks treatment. | ||
Medical condition: HCV RNA response to a multivalent IFN (Multiferon 6 MU q.d. + ribavirin standard dosed) in prior non-responders to SOC (peg-IFN + ribavirin) during treatment the initial 12 weeks. Results of HCV RN... | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: SE (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2009-017095-24 | Sponsor Protocol Number: AOP13007 | Start Date*: 2010-02-17 | |||||||||||
Sponsor Name:AOP Orphan Pharmaceuticals AG | |||||||||||||
Full Title: A phase III, randomized, multicenter, subject- and sponsor-blinded, placebo controlled study to compare the efficacy and safety of “Anagrelide retard” versus placebo in “at risk” subjects with Esse... | |||||||||||||
Medical condition: male and female "at risk" subjects with Essential Thrombocythaemia | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) SK (Completed) SI (Completed) LT (Completed) BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-001356-31 | Sponsor Protocol Number: PEN-PV | Start Date*: 2015-05-20 | |||||||||||
Sponsor Name:AOP Orphan Pharmaceuticals AG | |||||||||||||
Full Title: An open-label, single arm, Phase III study to assess the self-administration of AOP2014 using a pre-filled pen, developed for the treatment of Polycythemia Vera patients | |||||||||||||
Medical condition: Polycythemia Vera | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) SK (Completed) AT (Completed) CZ (Completed) BG (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-003410-41 | Sponsor Protocol Number: AOP18007 | Start Date*: 2014-01-13 | |||||||||||
Sponsor Name:AOP Orphan Pharmaceuticals AG | |||||||||||||
Full Title: A phase III randomized, multicenter, double-blind, active controlled study to compare the efficacy and safety of two different anagrelide formulations in patients with Essential Thrombocythemia (TE... | |||||||||||||
Medical condition: male or female patients with confirmed diagnosis of Essential Thrombocythemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) LT (Completed) BG (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-000249-38 | Sponsor Protocol Number: R118439 | Start Date*: 2019-01-25 | |||||||||||
Sponsor Name:University of Manchester | |||||||||||||
Full Title: Phase II trial of interleukin-1 receptor antagonist in intracerebral haemorrhage: BLOcking the Cytokine IL-1 in ICH | |||||||||||||
Medical condition: intracerebral haemorrhage | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-001357-17 | Sponsor Protocol Number: CONTINUATION-PV | Start Date*: 2014-11-03 | |||||||||||
Sponsor Name:AOP Orphan Pharmaceuticals AG | |||||||||||||
Full Title: An open-label, multicenter, phase IIIb study assessing the long-term efficacy and safety of AOP2014 and standard first line treatment (BAT) in patients with Polycythemia Vera who previously partici... | |||||||||||||
Medical condition: Polycythemia Vera | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) AT (Completed) CZ (Completed) PL (Completed) SK (Completed) BG (Completed) ES (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-000344-10 | Sponsor Protocol Number: 06_ENDO_49 | Start Date*: 2006-06-08 |
Sponsor Name:Christie Hospital | ||
Full Title: Multi-centre study of cabergoline alone and in combination with pegvisomant in the management of active acromegaly | ||
Medical condition: acromegaly | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) IE (Completed) | ||
Trial results: View results |
EudraCT Number: 2011-006100-12 | Sponsor Protocol Number: FANCOLEN-1 | Start Date*: 2013-04-12 | |||||||||||
Sponsor Name:FUNDACION PARA LA INVESTIGACION BIOMEDICA DEL HOSPITAL UNIVERSITARIO NIÑO JESUS | |||||||||||||
Full Title: Clinical Trial Phase I / II to evaluate the safety and efficacy of the infusion of autologous CD34+ cells transduced with a lentiviral vector carrying the FANCA gene (orphan drug) for patients with... | |||||||||||||
Medical condition: Fanconi anemia (Subtype A) | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.